Key clinical point: Patients with unresectable hepatocellular carcinoma needed higher relative dose intensity (RDI) to achieve an objective response with lenvatinib, but the therapeutic line did not impact overall survival, time to progression, or best response.
Major finding: RDI ≥0.8 during cycle 1 and RDI ≥0.4 during cycle 1 contributed to achievement of objective response with levatinib (odds ratio 3.28) and disease control (OR 4.85).
Study details: The data come from a retrospective study of 100 patients with unresectable hepatocellular carcinoma who received first- or later-line lenvatinib between April 2018 and December 2020 in a single center; they were assessed for time to objective response, disease control, overall survival, and time to progression.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Tokunaga T et al. Hepatol Res. 2021 Oct 9. doi: 10.1111/hepr.13720.